Tirzepatide vs Mounjaro: Same Molecule, Different Label, Different Cost

This is the most important sentence in this article: tirzepatide and Mounjaro contain the same molecule. They are not different drugs. Mounjaro is Eli Lilly’s brand name for tirzepatide as a treatment for type 2 diabetes. Zepbound is Eli Lilly’s brand name for the same molecule indicated for chronic weight management. Compounded tirzepatide is the same molecule prepared by a licensed compounding pharmacy under physician supervision. The mechanism, the receptor binding, and the clinical effects are the same.

What is different is the regulatory pathway, the manufacturer, the delivery system, the price, and the indication on the label. Most patients comparing tirzepatide and Mounjaro are not asking which molecule is better. They are asking which pathway to acquire the molecule makes the most sense for them in 2026. That is the question this article answers.

Three tirzepatide-based options are commonly compared:

• Mounjaro - Eli Lilly’s brand for tirzepatide, FDA-approved in 2022 for type 2 diabetes. Sold in prefilled single-dose pens at 2.5, 5, 7.5, 10, 12.5, and 15 mg strengths. List price approximately $1,069 per month.
• Zepbound - Eli Lilly’s brand for the same molecule, FDA-approved in 2023 for chronic weight management and in 2024 for obstructive sleep apnea in adults with obesity. Available in the same dose strengths in pens, plus single-dose vials through Lilly’s self-pay program. List price approximately $1,059 per month for pens; vials available for approximately $499 per month under the self-pay vial program for selected doses.
• Compounded tirzepatide - the same active ingredient prepared by a licensed 503A compounding pharmacy on a per-patient basis under physician supervision. Not an FDA-approved product, but legally compounded under specific clinical need. Price ranges from approximately $149 to $400 per month depending on dose, formulation, and provider.

Why Mounjaro and Zepbound are separated

Eli Lilly registered tirzepatide for two different uses and obtained two different FDA approvals. The diabetes-labeled product (Mounjaro) and the weight-management-labeled product (Zepbound) are clinically identical at the molecule level but carry different prescribing information and different insurance coverage profiles. For a patient with type 2 diabetes, Mounjaro is the on-label brand. For a patient without diabetes who is seeking weight management, Zepbound is the on-label brand. Both contain tirzepatide at the same dose strengths.

All clinical and pricing figures are sourced from Eli Lilly’s published pricing information and FDA-approved labels as of May 2026.

[Editor note: this section renders the interactive side-by-side comparison table. The full row-by-row content is captured in the Comparison Rows field — Mounjaro (gold accent) on the left, compounded tirzepatide (teal accent) on the right — covering the headline price ($1,069 vs $149), active ingredient, FDA-approved use, delivery format, manufacturer, and monthly cash cost.]

The most important distinction between Mounjaro and compounded tirzepatide is the regulatory pathway each one followed to reach patients. FDA approval is not a vague stamp; it is a defined process with specific requirements.

To win FDA approval for Mounjaro, Eli Lilly conducted multiple Phase 3 trials in patients with type 2 diabetes (the SURPASS trial program), submitted full chemistry, manufacturing, and controls documentation, demonstrated lot-to-lot consistency, sterility, stability, and bioequivalence, and continues to report post-marketing safety data to the FDA. The same was true for Zepbound (the SURMOUNT trial program for weight management). The Mounjaro prescribing information is available at the FDA’s drug labels database at accessdata.fda.gov.

Compounded tirzepatide does not go through this process. It is prepared by a licensed compounding pharmacy directly from a USP-grade active pharmaceutical ingredient, mixed with a sterile diluent and preservative, and dispensed in multi-dose vials. The FDA does not evaluate the safety, efficacy, or quality of compounded medications. State pharmacy boards regulate the compounding pharmacy, and the prescribing physician is responsible for clinical oversight.

The practical implication: when you take Mounjaro, you know exactly what is in the pen, that it was manufactured to standardized specifications, and that the same dose in the same pen has been given to millions of patients with documented outcomes. When you take compounded tirzepatide, the quality depends on the specific compounding pharmacy. This is why choosing a pharmacy with certified credentials and physician oversight matters.

Compounded medications in the United States are governed by two sections of the Food, Drug, and Cosmetic Act:

• Section 503A - covers traditional pharmacy compounding. A licensed pharmacist may compound a medication for an individual patient based on a specific prescription from a licensed prescriber. The product is intended to address a clinical need the FDA-approved medication does not meet, such as a different strength, dose form, or excipient profile. State pharmacy boards regulate the practice. Compounded 503A products are not FDA-approved and may not be advertised or marketed in commerce as if they were.
• Section 503B - covers outsourcing facilities that produce larger batches of compounded medications, often for hospital and clinic settings. 503B facilities operate under direct FDA oversight and may compound in advance of a specific prescription, but only under specific circumstances, the most common of which is a documented drug shortage on the FDA’s official shortage list.

The 2024 shortage resolution

From 2022 through early 2024, tirzepatide was on the FDA’s official shortage list because demand outpaced manufacturing. During that period, both 503A and 503B compounding of tirzepatide expanded substantially. In late 2024, the FDA designated the tirzepatide shortage as resolved. The agency’s announcement is available at fda.gov. With the shortage resolution, bulk 503B compounding of tirzepatide based on the shortage exception is no longer permitted.

What continues is 503A patient-specific compounding for patients whose clinical needs are not met by the brand product. The clinical reasons include patients who require a different dose strength than the brand pens provide, patients who cannot tolerate a specific excipient in the FDA-approved formulation, or patients for whom the standardized pen device presents a barrier to use. The prescribing clinician documents the clinical need on the prescription, and the compounding pharmacy fills it on a per-patient basis. Harbor operates within this 503A framework with physician oversight.

Cost is the single largest reason patients ask about compounded tirzepatide. The arithmetic is straightforward:

Mounjaro cash price

The Mounjaro list price is approximately $1,069 per month. Eli Lilly offers a savings card that can reduce out-of-pocket cost to as low as $25 per month for commercially insured patients with type 2 diabetes coverage, subject to plan eligibility and a maximum monthly savings cap. Self-pay patients without insurance pay close to list price unless they qualify for patient assistance.

Mounjaro through insurance

Commercial insurance and Medicare Part D commonly cover Mounjaro for type 2 diabetes with prior authorization, often requiring A1C documentation and step therapy through metformin and other oral agents first. Coverage for off-label weight-loss use of Mounjaro is uncommon. Patients seeking insurance-covered tirzepatide for weight management are typically directed to Zepbound, which has obesity-specific coverage on some plans.

Compounded tirzepatide pricing

Compounded tirzepatide ranges from approximately $149 to $400 per month depending on the compounding pharmacy, dose strength, and the prescribing telehealth program. Harbor offers compounded tirzepatide at $149 per month with a 12-month results guarantee, 24/7 clinician access, and on-time refill protection. The pricing reflects direct procurement of USP-grade tirzepatide active ingredient, on-site sterile compounding at a 503A pharmacy, and the absence of brand royalty and proprietary injection device costs.

Most patients fit one of four scenarios. The right choice depends on diagnosis, coverage, and personal priorities.

1. You have type 2 diabetes with good coverage

If you have type 2 diabetes and your insurance covers Mounjaro through prior authorization, brand Mounjaro is the straightforward answer. The Lilly savings card combined with insurance coverage can bring out-of-pocket cost to under $50 per month for many commercially insured patients. The medication is the FDA-approved standardized product. There is no clinical reason to compound when the brand is affordable.

2. You are pursuing weight loss and want an on-label brand

If your primary goal is weight loss and you want the FDA-approved brand, Zepbound is the answer, not Mounjaro. Zepbound is tirzepatide labeled for chronic weight management. Mounjaro for weight loss is off-label. Insurance coverage for Zepbound varies by plan; if your plan covers it, that is the most regulatorily clean path.

3. You are pursuing weight loss and the brand cost is prohibitive

If neither Mounjaro nor Zepbound is covered by your insurance and the cash price of $1,000+ per month is not realistic, compounded tirzepatide through a licensed 503A pharmacy with physician oversight is a reasonable path. The active ingredient is the same. The trade-offs are the regulatory pathway, the manual draw-and-inject format, and the responsibility to choose a reputable pharmacy. Harbor’s compounded tirzepatide program is built specifically for this case, with US-certified 503A pharmacies, physician oversight through the patient portal, and a 12-month results guarantee.

4. You need a clinical accommodation the brand cannot provide

If you have a documented allergy to an excipient in the Mounjaro or Zepbound pens, or you require a non-standard dose between the standard escalation steps, 503A compounding is the legitimate pathway. Your prescribing clinician documents the clinical need on the prescription. The compounding pharmacy fills it on a per-patient basis. This is the original purpose of 503A compounding and the path that remains fully aligned with FDA policy.

Whether to choose compounded tirzepatide depends in large part on confidence in the compounding pharmacy. Not all compounding pharmacies are equal, and the FDA has issued warnings about adverse events linked to non-licensed or unregulated sources. The questions a patient should ask before starting compounded tirzepatide are:

1. Is the pharmacy licensed and in good standing with its state pharmacy board? Verify through your state pharmacy board’s online directory.
2. Is the pharmacy operating under 503A oversight with patient-specific prescriptions, not bulk-compounded inventory? The legal compounding pathway in 2026 is patient-specific 503A.
3. Where does the active ingredient come from? Reputable compounders source USP-grade tirzepatide active pharmaceutical ingredient from FDA-registered facilities and can provide certificates of analysis on request.
4. Who is the prescribing clinician and how can you reach them? Avoid programs that bypass meaningful clinical oversight. Harbor assigns every member to a board-certified US physician through the patient portal with 24/7 access.
5. What is the dose, concentration, and how is the dose drawn and injected? Standard compounded tirzepatide protocols match the Mounjaro and Zepbound titration schedules (2.5 mg starting dose, escalating every 4 weeks).

Harbor’s compounded tirzepatide program is built for patients in scenarios three and four above. The program operates within the 503A framework with physician oversight. Every Harbor member is matched to a board-certified US physician who reviews the intake, writes the prescription with documented clinical need, and is reachable through the patient portal 24/7 for dose adjustments, side effect management, and questions.

Harbor uses US-certified 503A compounding pharmacies that source USP-grade tirzepatide active pharmaceutical ingredient. The dosing schedule matches the FDA-approved tirzepatide brand labels. Members receive compounded tirzepatide in multi-dose vials with the syringes needed to draw and inject the prescribed dose. The Harbor program includes dietitian support in the maintenance phase after the medication ends, on-time refill protection, and a 12-month results guarantee. Members can compare Harbor side-by-side with other GLP-1 programs on our compare page, and read more about the underlying science of GLP-1 medications. For deeper background on tirzepatide specifically, see our guide to how tirzepatide’s dual GLP-1 / GIP mechanism produces weight loss.